Vandetanib + Gemcitabine + Oxaliplatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Incurable Solid Malignancy
Conditions
Advanced Incurable Solid Malignancy
Trial Timeline
Feb 1, 2009 → Dec 1, 2010
NCT ID
NCT00660725About Vandetanib + Gemcitabine + Oxaliplatin
Vandetanib + Gemcitabine + Oxaliplatin is a phase 1 stage product being developed by AstraZeneca for Advanced Incurable Solid Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT00660725. Target conditions include Advanced Incurable Solid Malignancy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00660725 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Incurable Solid Malignancy